Clincosm LogoSign in Get a demo

Platinum-Resistant Ovarian Carcinoma

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma Trial in Bethesda, Boston (Biopsy,

Recruiting
  • Advanced Fallopian Tube Carcinoma
  • +21 more
  • Biopsy
  • +2 more
  • Bethesda, Maryland
  • +2 more
Jan 25, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +20 more
  • Pembrolizumab
  • Ziv-Aflibercept
  • Tampa, Florida
  • +8 more
Jan 3, 2023

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
Oct 19, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

Recruiting
  • Bone Sarcoma
  • +15 more
  • Aldesleukin
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022